Chart Of The Day: Here’s What Happens When A Money Losing Biotech’s Phase 2 Study Fails…

Nivalis Therapeutics (NVLS) plunged over 50% after it said its Phase 2 study evaluating cavosonstat failed to meet the primary endpoint in adult patients with cystic fibrosis.